INTERVIEW: Oxford Biodynamics Extending precision medicine study

Oxford Biodynamics Plc (LON:OBD) Director of Business Development & Head of Statistics Dr. Ewan Hunter talks to DirectorsTalk about the publication of a paper in the Journal of Translational Medicine. Ewan provides a summary of the paper, explains the impact towards precision medicine, how this work fits into the landscape of chromosome architecture, regulation of gene expression and the control of the genome via the non-coding genome. Ewan also explains how OBD is extending this work.

Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    EpiSwitch technology in Alzheimer’s disease

    Alzheimer’s disease (AD) is the most common form of dementia, and it accounts for an estimated 60% – 80% of cases. The hallmark pathologies of AD are the progressive accumulation of the protein fragment beta-amyloid (plaques)

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations(DNA protein complexes) that regulate normal and disease biology

    Oxford BioDynamics

    Holos Life Sciences using EpiSwitch

    Epigenetics represents the impact of the combination of genetic, lifestyle and environmental factors on humans. We utilise EpiSwitch™, a proprietary biomarker discovery platform licensed from our AIM listed shareholder Oxford Biodynamics Plc. Based on the latest advances in gene

    Oxford BioDynamics

    Episwitch Methodology

    Oxford BioDynamics’ EpiSwitchTM platform is the first industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”). CCSs provide a robust, stable framework of

    Oxford BioDynamics

    5 Ways to Help Kids Cope with a Parent’s ALS

    One of my biggest concerns is how my husband’s ALS will affect our children. They were both under 5 when Todd was diagnosed and while they are growing up, their father continues to lose strength. A

    Oxford BioDynamics

    EpiSwitch Technology

    EpiSwitch™ is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”).  CCSs can provide a compelling, stable framework from which changes in the regulation of

    Oxford BioDynamics

    Rare Disease Day 2020

    An abundance of events are afoot around the world to mark Rare Disease Day 2020 on Feb. 29. The activities are focused on heightening awareness about rare diseases and the hundreds of millions of individuals they are thought

    Oxford BioDynamics

    Oxford BioDynamics’ EpiSwitchFeatured in Presentations

    Data yielded by application of OBD’s 3D genome architecture technology platform, EpiSwitch™ was presented at The Society for Immunotherapy of Cancer’s 34th Annual Meeting. The poster presentations indicate that the biomarkers identified by EpiSwitch, using blood samples

    Oxford BioDynamics

    Dementia rates in Europe to double by 2050

    Today, at a European Parliament lunch debate hosted by Christophe Hansen MEP (Luxembourg), Alzheimer Europe launched a new report presenting the findings of its collaborative analysis of recent prevalence studies and setting out updated prevalence rates

    Oxford BioDynamics

    EpiSwitch technology

    EpiSwitch™ is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”). CCSs can provide a compelling, stable framework from which changes in the regulation of a

    Oxford BioDynamics

    What is ALS?

    ALS, also known as Motor Neuron Disease (MND), Lou Gehrig’s Disease, and Charcot’s disease, is a progressive neurodegenerative disease which attacks motor neurons in the brain and spinal cord resulting in the wasting away of muscle

    Oxford BioDynamics

    Oxford Biodynamics publish Annual Report

    Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of biomarkers based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry, today announced that copies of its annual report

    Oxford BioDynamics

    What is EpiSwitchTM and how is it used?

    Grounded in Epigenetics Oxford BioDynamics’ EpiSwitch technology is based on epigenetics: mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune diseases, neurologic

    Oxford BioDynamics

    What is ALS?

    Amyotrophic Lateral Sclerosis (ALS) is a progressive neurological disease that destroys nerve cells in the brain  and the spinal cord and causes disability. It is also known as Lou Gehrig’s disease. The term “A-myo-trophic” is derived from the